Healthy
Conditions
Keywords
Indomethacin, Double-guidewire technique, Adverse events, PEP, PD stenting
Brief summary
Rectal indomethacin and pancreatic duct (PD) stenting (PDS) are recommended for the prevention of post-ERCP pancreatitis (PEP). However, the effects of the combination of the two methods on preventing PEP are controversial. We hypothesized that some group of patients with difficult cannulation might benefit from the combination of indomethacin plus PDS (IP) compared with indomethacin alone (IN).
Interventions
DEVICEPancreatic duct stenting
A stent placed in the pancreatic duct to reduce PEP possibly by relieving pancreatic ductal hypertension that develops because of transient procedure-induced edema and stenosis of the pancreatic orifice
Sponsors
Air Force Military Medical University, China
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Patients underwent diagnostic or therapeutic ERCP 2. With native papilla 3. With difficult cannulation (cannulation time \>10min or cannulation attempts \>5 times or inadvertently PD cannulation ≥1) 4. Receiving post-ERCP rectal indomethacin
Exclusion criteria
1. Patients with indications of PD cannulation 2. No attempt of cannulation due to inaccessible papilla 3. Non-difficult cannulation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall PEP | 30 days | PEP was diagnosed if there was a worsening or new onset of pain in the upper abdomen, an elevation in serum amylase of at least three times of the upper limit of the normal range 24h after the procedure and requiring at least two nights of hospitalization. |
Secondary
| Measure | Time frame |
|---|---|
| Overall ERCP related complication | 30 days |
Countries
China
Outcome results
None listed